Moderate to severe plaque psoriasis
Conditions
Interventions
Combination Group:Secukinumab combined with Apremilast
Sponsors
Beijing Luhe Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old, no gender restrictions; 2. Meets the clinical diagnosis criteria for moderate-to-severe plaque psoriasis (BSA >= 10%); 3. Following investigator assessment, patients are scheduled to receive treatment with Secukinumab; 4. Has not received treatment with biologics or Apremilast, and has not participated in any other clinical trials within the past 3 months. 5. Voluntarily sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergic to the active ingredient or any excipient in the investigational drug; 2. Individuals with clinically significant active infections (e.g., active tuberculosis), pregnancy/lactation, plans for pregnancy within 2 weeks prior to study initiation or within 3 months after study completion, malignant tumors, or history of psychiatric disorders. 3. Unable to comply with trial treatment and follow-up; 4. Other circumstances deemed unsuitable for participation in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psoriasis Area and Severity Index,PASI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Static Physician’s Global Assessment,sPGA;Body Surface Area,BSA;Dermatology Life Quality Index,DLQI; | — |
Countries
China
Contacts
Public ContactYifei Liu
Beijing Luhe Hospital, Capital Medical University
Outcome results
None listed